Keros Therapeutics, Inc.

NasdaqGM:KROS Stok Raporu

Piyasa değeri: US$2.7b

Keros Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Keros Therapeutics CEO'su Jas Seehra, Dec2015 tarihinde atandı, in görev süresi 8.92 yıldır. in toplam yıllık tazminatı $ 8.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.3% maaş ve 92.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.67% ine doğrudan sahiptir ve bu hisseler $ 18.34M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 4.7 yıldır.

Anahtar bilgiler

Jas Seehra

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi7.3%
CEO görev süresi8.9yrs
CEO sahipliği0.7%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi4.7yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Keros Therapeutics prices equity offering at $50

Nov 13

CEO Tazminat Analizi

Jas Seehra'un ücretlendirmesi Keros Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

Tazminat ve Piyasa: Jas 'nin toplam tazminatı ($USD 8.93M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.60M ).

Tazminat ve Kazançlar: Jas şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Jas Seehra (68 yo)

8.9yrs

Görev süresi

US$8,932,076

Tazminat

Dr. Jasbir S. Seehra, also known as Jas, Ph D., has been Chief Executive Officer and Director at Keros Therapeutics Inc., since December 2015 and is its Chair of the Board since July 1, 2024 and was its Pr...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.67%
$ 18.3m
Christopher Rovaldi
President & COO2.8yrsUS$4.69m0%
$ 0
Keith Regnante
Chief Financial Officer4.8yrsUS$2.20m0%
$ 0
Esther Cho
Senior VP4.6yrsVeri yokVeri yok
Robin Wagner
Senior Vice President of Human Resources3.4yrsVeri yokVeri yok
John Oram
Senior Vice President of Program & Portfolio Management1.6yrsVeri yokVeri yok
Yung Chyung
Chief Medical Officerno dataVeri yokVeri yok

3.4yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: KROS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jasbir Seehra
CEO & Chair of the Board8.9yrsUS$8.93m0.67%
$ 18.3m
Carl Gordon
Independent Director4.7yrsUS$409.37kVeri yok
Tomer Kariv
Independent Director4.8yrsUS$385.86kVeri yok
Jean-Jacques Bienaime
Lead Independent Directorless than a yearVeri yok0.00053%
$ 14.4k
Julius Knowles
Independent Director8.6yrsUS$388.48k0.0032%
$ 86.3k
Mary Gray
Independent Director3.9yrsUS$396.98k0.12%
$ 3.1m
Ran Nussbaum
Independent Director8.6yrsUS$390.56k0%
$ 0
Alpna Seth
Independent Director1.5yrsUS$1.02m0.044%
$ 1.2m
Nima Farzan
Independent Director4.7yrsUS$388.48k0.094%
$ 2.5m
Mary Bouxsein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Vicki Rosen
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Paul Yu
Member of Scientific Advisory Boardno dataVeri yokVeri yok

4.7yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KROS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).